Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2024-04-03 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Total Voting Rights and Block Listing Return
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from MaxCyte, Inc. regarding 'Total Voting Rights' and a 'Block Listing Return'. These filings are standard regulatory disclosures required by the London Stock Exchange (AIM Rules) when a company issues new shares or updates its capital structure. While it mentions share issuance, it is primarily a regulatory notification of voting rights and block listing status rather than a standalone share repurchase or a major shareholding notification. Therefore, it fits best under the 'Regulatory Filings' category.
2024-04-03 English
Signing of Strategic Platform License
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic platform license agreement between MaxCyte, Inc. and Be Biopharma. It details a business partnership and licensing deal rather than a financial report, governance update, or shareholder meeting material. Since it is a general corporate announcement regarding business operations and partnerships that does not fit into more specific categories like M&A or capital changes, it is classified as a Regulatory Filing (RNS).
2024-04-02 English
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director (John Johnston) exercising options and selling shares. The text explicitly includes the standard regulatory disclosure table for PDMR dealings, which is the hallmark of a Director's Dealing filing.
2024-04-02 English
Director's Dealing 2024
Director's Dealing
2024-03-28 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-03-25 English
Grant of Options, RSUs and PSUs and PDMR Dealing
Director's Dealing Classification · 1% confidence The document is a formal notification of share-based compensation (options, RSUs, and PSUs) granted to company executives (PDMRs). It explicitly includes the 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES' table, which is the standard regulatory format for reporting insider dealings and management share transactions. While it involves directors, the specific nature of the disclosure regarding grants of equity instruments to management falls under the 'Director's Dealing' category.
2024-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.